Skip to content

Black Bird Biotech, Inc.: 10-Q filed 2019-11-20

What Black Bird Biotech, Inc. reported in its quarterly report filed 2019-11-20 (fiscal Q3 2019): 14 published measures, 50 facts as tagged in accession 0001104659-19-065762.

This filing

Form
10-Q (quarterly report)
Filed
2019-11-20
Fiscal period
fiscal Q3 2019
Accession
0001104659-19-065762 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All Black Bird Biotech, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2019-09-301,534USD
At 2018-12-314,733USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2019-09-301,109,612USD
At 2018-12-311,023,561USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2019-09-30-1,108,078USD
At 2019-06-30-1,077,222USD
At 2019-03-31-1,048,244USD
At 2018-12-31-1,018,828USD
At 2018-09-30-977,327USD
At 2018-06-30-954,179USD
At 2018-03-31-920,486USD
At 2017-12-31-897,718USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2019-07-01 to 2019-09-30-30,856USD92
2019-01-01 to 2019-09-30-89,250USD273
2018-07-01 to 2018-09-30-23,148USD92
2018-01-01 to 2018-09-30-79,609USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2019-01-01 to 2019-09-30-54,371USD273
2018-01-01 to 2018-09-30-40,350USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2019-01-01 to 2019-09-3051,172USD273
2018-01-01 to 2018-09-3043,510USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2019-09-30-8,682,995USD
At 2018-12-31-8,593,745USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2019-07-01 to 2019-09-30-20,244USD92
2019-01-01 to 2019-09-30-58,432USD273
2018-07-01 to 2018-09-30-13,622USD92
2018-01-01 to 2018-09-30-51,797USD273

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2019-07-01 to 2019-09-3010,612USD92
2019-01-01 to 2019-09-3030,818USD273
2018-07-01 to 2018-09-309,526USD92
2018-01-01 to 2018-09-3027,812USD273

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2019-07-01 to 2019-09-3020,244USD92
2019-01-01 to 2019-09-3058,432USD273
2018-07-01 to 2018-09-3013,622USD92
2018-01-01 to 2018-09-3051,797USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2019-09-3085,970,665shares
At 2018-12-3185,970,665shares

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2019-07-01 to 2019-09-30-30,856USD92
2019-01-01 to 2019-06-30-28,978USD181
2019-01-01 to 2019-03-31-29,416USD90
2018-07-01 to 2018-09-30-23,148USD92
2018-04-01 to 2018-06-30-33,693USD91
2018-01-01 to 2018-03-31-22,768USD90

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2019-07-01 to 2019-09-3020,244USD92
2019-01-01 to 2019-09-3058,432USD273
2018-07-01 to 2018-09-3013,622USD92
2018-01-01 to 2018-09-3051,797USD273

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2019-07-01 to 2019-09-30-10,612USD92
2019-01-01 to 2019-09-30-30,818USD273
2018-07-01 to 2018-09-30-9,526USD92
2018-01-01 to 2018-09-30-27,812USD273

Inspect the source

Entity
Black Bird Biotech, Inc. / CIK 0001409999
Captured
SEC response SHA-256
df936db10ff162447a769152b36bd1ddff9f21ac96d53dd4e87253b660581055

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001409999.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))